Results 11 to 20 of about 16,238 (237)

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system [PDF]

Frontiers in Pharmacology
BackgroundAnakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed.
Hao Liu, Wei Yan, Jinsong Li, Dezhi Yan, Di Luo   +4 more
doaj   +2 more sources

The effect of IL-1β inhibitor canakinumab (Ilaris®) on IL-6 production in human skeletal muscle cells. [PDF]

PLoS ONE
Muscle inflammation is one of the hallmarks of Duchenne muscular dystrophy (DMD). Dystrophin-deficient skeletal muscle cells produce higher levels of pro-inflammatory cytokines such as interleukin 1β (IL-1β) in response to toll-like receptor stimulation ...
Anna Cordeiro-Santanach, Fiorella Morales, Maria Del Carmen Parquet, Kitipong Uaesoontrachoon, Joyce Rowsell, Jordan Warford, Wilson Wu, Pia Elustondo, Eric P Hoffman, Kanneboyina Nagaraju   +9 more
doaj   +2 more sources

Age-Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database. [PDF]

Pharmacol Res Perspect
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Wang Y, Lam N, Huang X, Jiao Y.
europepmc   +2 more sources

OR10-006 - Canakinumab in patients with TRAPS [PDF]

, 2013
Helen J. Lachmann, Laura Obici, A Meini, Vincent Tormey, Kenneth Abrams, Nicole L. Davis, Christopher Andrews, SG Bhansali, Marco Gattorno   +8 more
openalex   +3 more sources

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases

Frontiers in Pediatrics, 2021
Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received canakinumab treatment for at least 6 months due to colchicine resistance or ...
Burcu Bozkaya Yücel, Ozlem Aydog, Ozlem Aydog, Hulya Nalcacioglu, Ayşegül Yılmaz   +4 more
doaj   +1 more source

Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States

Pediatric Rheumatology Online Journal, 2021
Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood.
Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom   +9 more
doaj   +1 more source

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

Frontiers in Pediatrics, 2022
ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS.
Mikhail M. Kostik, Eugenia A. Isupova, Konstantin Belozerov, Tatyana S. Likhacheva, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Evgeny N. Suspitsin, Rinat Raupov, Vera V. Masalova, Irina A. Chikova, Margarita F. Dubko, Olga V. Kalashnikova, Vyacheslav G. Chasnyk, Randy Q. Cron   +13 more
doaj   +1 more source

Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases

The Turkish Journal of Pediatrics, 2020
Background and Objectives. The aim of this observational retrospective cohort study was to demonstrate indications and response rates of the patients with pediatric rheumatic diseases that used canakinumab. Method. The files of the patients
Mustafa Çakan, Şerife Gül Karadağ, Nuray Aktay Ayaz   +2 more
doaj   +1 more source

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Scientific Reports, 2021
Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated ...
Wen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, Chih-Hung Chuang, Yi-An Cheng, I.-Ju Chen, Hui-Ju Liu, Kai-Wen Ho, Tzu-Yi Liao, En-Shuo Liu, Ting-Yi Wu, Long-Sen Chang, Shih-Ting Hong, Tian-Lu Cheng   +13 more
doaj   +1 more source

Association between C-reactive protein with all-cause mortality in ELSA-Brasil cohort [PDF]

, 2020
Background: High-sensitive C-reactive protein (hsCRP) has been proposed as a marker of incident cardiovascular disease and vascular mortality, and it may also be a marker of non-vascular mortality.
Alvim Matos, Sheila M., Azevedo, Douglas R. M., Barreto, Sandhi M., Cappuccio, Francesco P., Giatti Gonçalves, Luana, Griep, Rosane H., Ji, Chen, Maluf, Chams B., Miller, Michelle A., Ribeiro, Luiz P., Vidigal, Pedro G.   +10 more
core   +3 more sources